- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 04.03. | Roche pumps $480M into South Korea biopharma industry to establish global trial 'ecosystem' | ||
| 04.03. | Bayer tosses 1 Pompe gene therapy from $2B AskBio buyout to focus on alternative option | ||
| 04.03. | UCB enters TCE space with $1.1B deal for Chinese biotech's autoimmune candidate | ||
| 04.03. | Teva bags $400M deal with Blackstone to fund Sanofi-partnered IBD drug | ||
| 03.03. | FDA details rationale for rejecting rare disease gene therapy from Regenxbio | ||
| 03.03. | Theravance halves headcount, ends all R&D work after phase 3 rare disease fail | ||
| 03.03. | New cancer cases prompt Kyowa to discontinue late-stage autoimmune disease program | ||
| 03.03. | Biohaven reduces scope of R&D cutbacks as pipeline progresses | ||
| 02.03. | Boehringer axes MASH deal with OSE as biotech continues to whittle down pipeline | ||
| 02.03. | TCE biotech Candid Therapeutics scores Nasdaq listing via reverse merger with rare disease-focused Rallybio | ||
| 02.03. | Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout | ||
| 02.03. | FDA fully releases clinical hold on Intellia CRISPR gene therapy trials | ||
| 02.03. | UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy | ||
| 02.03. | United Therapeutics' phase 3 win tees up filing to challenge J&J in cardiac condition | ||
| 02.03. | BioAtla lays off 70% of workforce, searches for buyers for antibody pipeline | ||
| 02.03. | Lynk points to phase 3 eczema win as more proof of next-gen JAK inhibitor's potential | ||
| 02.03. | Roche reports another phase 3 multiple sclerosis win but deaths add to safety questions | ||
| 02.03. | Aardvark pauses phase 3 metabolic drug study over 'cardiac observations,' sinking sock | ||
| 27.02. | Atrium Therapeutics arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates | ||
| 27.02. | Earendil pens $885M pact to use WuXi XDC's linker tech for next-gen ADCs | ||
| 27.02. | Generate scores largest biotech IPO since 2024 with $400M Nasdaq listing | ||
| 26.02. | 'Like talking to a brick wall': Senate hearing takes aim at FDA's rare disease review process | ||
| 26.02. | Analysts see potential in MDMA drug after AtaiBeckley reports improvements in anxiety trial | ||
| 26.02. | Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial | ||
| 26.02. | Accent halts solid tumor trial over adverse events, pivots to other lead cancer program |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.